Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
BackgroundNiraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Nevertheless, as of the present moment, there are limited instances demonstrating favorable outcomes stemming from ni...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Frontiers Media S.A.,
2024-06-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sailkapena: |
A1234.567 |
|---|---|
| Alea 1 | Eskuragarri |